Literature DB >> 26202829

Nutraceuticals for Serum Lipid and Blood Pressure Control in Hypertensive and Hypercholesterolemic Subjects at Low Cardiovascular Risk.

Alberto Mazza1, Salvatore Lenti, Laura Schiavon, Marco Zuin, Maria D'Avino, Emilio Ramazzina, Edoardo Casiglia.   

Abstract

INTRODUCTION: Primary cardiovascular (CV) prevention may be achieved by lifestyle/nutrition changes, although a relevant role is now emerging for specific, functional foods and nutraceutical compounds (NCs). The aim of this study was to investigate the efficacy and safety of NCs in lowering blood pressure (BP) and improving lipid profile, when added to diet and lifestyle management versus diet alone in a group of patients with hypertension (HT) and hypercholesterolemia (HCh) with low CV risk.
METHODS: Sixty-six patients with HT and HCh with grade 1 essential HT (mean age 56.0 ± 4.6 years) without history of CV diseases or organ damage were analyzed. These subjects were started on one tablet of an NC-containing red yeast rice, policosanol, berberine, folic acid and coenzyme Q10 once daily for 6 months and were age and gender matched with subjects following a diet program. Differences in clinic BP, 24-h ambulatory BP (24 h-ABPM), serum total cholesterol, low-density and high-density lipoprotein cholesterol (LDL-C and HDL-C) and triglyceride values were compared by analysis of variance.
RESULTS: In the treatment group, a significant reduction of systolic 24 h-ABPM (141.6 ± 6.4 vs. 136.2 ± 4.8 mmHg; p < 0.05) and pulse pressure 24 h-ABPM (52.6 ± 7.2 vs. 47.3 ± 5.4 mmHg; p < 0.05) was found at the end of follow-up. A reduction of total cholesterol (-19.2%), LDL-C (-17.4%) and triglycerides (-16.3%) was observed (p < 0.001 for all); HDL-C remained unchanged. No difference was found in the control group.
CONCLUSIONS: The tested NCs was found to be safe, well tolerated and effective in reducing mean 24-h systolic and 24-h pulse pressure and in improving lipid pattern.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26202829     DOI: 10.1007/s12325-015-0229-x

Source DB:  PubMed          Journal:  Adv Ther        ISSN: 0741-238X            Impact factor:   3.845


  5 in total

Review 1.  The role of nutraceuticals in the prevention of cardiovascular disease.

Authors:  Bozena Sosnowska; Peter Penson; Maciej Banach
Journal:  Cardiovasc Diagn Ther       Date:  2017-04

Review 2.  Expatiating the Pharmacological and Nanotechnological Aspects of the Alkaloidal Drug Berberine: Current and Future Trends.

Authors:  Tapan Behl; Sukhbir Singh; Neelam Sharma; Ishrat Zahoor; Ali Albarrati; Mohammed Albratty; Abdulkarim M Meraya; Asim Najmi; Simona Bungau
Journal:  Molecules       Date:  2022-06-09       Impact factor: 4.927

3.  The Effects of a New Generation of Nutraceutical Compounds on Lipid Profile and Glycaemia in Subjects with Pre-hypertension.

Authors:  Alberto Mazza; Laura Schiavon; Gianluca Rigatelli; Gioia Torin; Salvatore Lenti
Journal:  High Blood Press Cardiovasc Prev       Date:  2019-07-27

Review 4.  A review of the effects of Berberis vulgaris and its major component, berberine, in metabolic syndrome.

Authors:  Jamshid Tabeshpour; Mohsen Imenshahidi; Hossein Hosseinzadeh
Journal:  Iran J Basic Med Sci       Date:  2017-05       Impact factor: 2.699

5.  Integrated Metagenomics and Metabolomics to Reveal the Effects of Policosanol on Modulating the Gut Microbiota and Lipid Metabolism in Hyperlipidemic C57BL/6 Mice.

Authors:  Zhenya Zhai; Jianping Liu; Kai-Min Niu; Chong Lin; Yue Tu; Yichun Liu; Lichuang Cai; Huiping Liu; Kexian Ouyang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-11       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.